Oxybutynin Tablet, Film Coated, Extended Release
Product Images NDC 0615-8220

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxybutynin (NDC 0615-8220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin Chloride Extended-release Tablet (Oxybutynin Chloride Er Tabs Usp 10 mg 1)

Chemical structure diagram of oxybutynin hydrochloride showing its molecular composition with labeled carbon chains, functional groups, and hydrochloride salt.*

FDA Label Image

Oxybutynin Chloride Extended Release Tablets (Oxybutynin Chloride Er Tabs Usp 10 mg 2)

A line graph comparing the mean plasma R-oxybutynin concentration (ng/mL) over 24 hours between oxybutynin chloride extended-release tablets 10 mg once daily and oxybutynin 5 mg three times daily. The x-axis represents time in hours, and the y-axis shows mean plasma concentration with error bars.*

FDA Label Image

Oxybutynin Chloride Extended Release Tablets (Oxybutynin Chloride Er Tabs Usp 10 mg 3)

A line graph showing mean R-oxybutynin plasma concentration (ng/mL) over time (hours). Data points are plotted from 0 to 24 hours with peak concentrations around 4-5 hours, followed by a decline. Error bars represent variability at each time point.*

FDA Label Image

Oxybutynin Chloride Er Tablets (Oxybutynin Chloride Er Tabs Usp 10 mg 4)

A data table and bar plot chart showing results from two studies measuring the number of urge urinary incontinence episodes per week. It compares mean baseline episodes and mean changes from baseline (with standard deviations and confidence intervals) between oxybutynin chloride extended release tablets and placebo groups. Study 1 shows a statistically significant difference, while Study 2 does not.*

FDA Label Image

Oxybutynin Chloride Er Tablets (Oxybutynin Chloride Er Tabs Usp 10 mg 5)

A comparative figure showing mean change (±SD) in episodes per week from baseline between oxybutynin chloride extended release tablets and oxybutynin. The chart includes a table with study data, sample sizes, mean baseline values, mean changes, and 95% confidence intervals for the difference between the treatments and placebo.*

FDA Label Image

Principal Display Panel (Oxybutynin Chloride ER Tabs USP 10 mg)

Label for oxybutynin chloride extended-release (ER) tablets USP 10 mg manufactured by Cadila for Zydus and packaged by Vanguard Labs. The label includes the NDC 0615-8220 and features lot and expiration date placeholders. It instructs storage at controlled room temperature and dispensing in a tight container, protecting from moisture and humidity. The label also includes a dosage instruction note to swallow tablets whole without chewing, dividing, or crushing. Multiple small barcode labels for oxybutynin chloride ER 10 mg tablets are displayed for institutional use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.